Cancer Immunotherapy Market

Cancer Immunotherapy Market Study by Monoclonal Antibodies, Immune Checkpoint Inhibitors, Immune System Modulators, and Cancer Immunotherapy Vaccines from 2024 to 2034

Analysis of Cancer Immunotherapy Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Cancer Immunotherapy Market (2024 to 2034)

The global cancer immunotherapy market is set to garner US$ 159.2 billion in revenue in 2024, according to Fact.MR, a market research and intelligence provider. Worldwide demand for cancer immunotherapies is projected to increase at a CAGR of 10% and reach a market value of US$ 412.8 billion by 2034.

Rising popularity of immunotherapy treatment due to its effective results is set to boost the overall market growth during the forecast period. The majority of leading companies are focused on the production of advanced drug solutions to support the effectiveness of immunotherapies. Furthermore, these industry giants are investing heavily in research and development activities.

The COVID-19 pandemic opened up new growth prospects for key manufacturers to focus on the production of anti-cancer drugs and cancer therapeutics. Need to prevent complications among cancer patients infected by the coronavirus also exacerbated the need for advanced critical care. The current scenario showcases that the growing prevalence of cancer and the importance of disbursing effective therapeutic approaches for cancer are driving the focus of governments on increased healthcare spending worldwide.

In most cancer cases, surgical procedures are opted to remove the tumor. Growing need for novel delivery approaches to cancer treatment is leading to the integration of peptide-based therapies and peptide-based drugs for effective results. These are some of the emerging cancer immunotherapy market trends to be followed over the coming years.

  • The North American cancer immunotherapy market size is calculated to reach US$ 100.3 billion by 2034.
  • East Asia is expected to capture 22.4% of the global cancer immunotherapy market share in 2024.
Report Attribute Detail
Cancer Immunotherapy Market Size (2024E) US$ 159.2 Billion
Forecasted Market Value (2034F) US$ 412.8 Billion
Global Market Growth Rate (2024 to 2034) 10% CAGR
South Korea Market Value (2034F) US$ 22 Billion
Cancer Immunotherapy Vaccine Demand Growth (2024 to 2034) 10.1% CAGR
Key Companies Profiled Eli Lilly and Company; Pfizer, Inc.; Spectrum Pharmaceuticals, Inc.; GlaxoSmithKline Plc.; Amgen Inc.; Bristol-Myers Squibb Company; Janssen Biotech, Inc.; Novartis AG; AstraZeneca Plc.; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Sanofi; Takeda Pharmaceuticals; Immunocore, Ltd.

Don't Need a Global Report?

save 40%! on Country & Region specific reports

Which Dynamics are Influencing the Popularity of Cancer Immunotherapies?

“Novel Cancer Biomarkers Offering Effective Analysis for Immunotherapies”

Some of the leading companies are focusing on the use of novel biomarkers for effective cancer diagnosis and treatment. Biomarkers are effective cancer diagnostic indicators that provide full cancer analysis from the type of cancer to what kind of molecular dysregulation caused the progression of the disease. Development of biomarkers for immunotherapy at the cellular, soluble, and genomic levels is set to boost the profits of key producers over the coming years. Some of the biomarkers in immunotherapy include serum proteins, receptor expression patterns, and tumor microenvironment biomarkers.

“Increasing Cancer Burden Spurring Demand for Advanced Cancer Immunotherapies”

  • According to the National Center for Biotechnology Information, in 2023, 1,958,310 new cancer cases and 609,820 cancer deaths were projected to occur in the United States.
  • As per analysis by the World Health Organization (WHO), breast cancer is one of the most common malignancies in women worldwide.
  • According to the same source, in 2022, the number of females living with breast cancer was around 2.3 million, and 670,000 deaths were noted due to breast cancer across the globe.

Global cases of cancer are expected to increase at a swift pace over the next 10 years. As such, governments across the world are investing heavily in the development of sustainable infrastructure for disseminating cancer by providing effective diagnostics and treatment measures. These aspects are set to offer high-growth opportunities for cancer immunotherapy providers.

Why is Cancer Immunotherapy a High-Growth Yet Challenging Field?

“Capital-Intensive Nature and Low Success Chances of Immunotherapy”

Several studies show that cancer is an extremely complex disease, and there is no single cure that can prove to be effective for all patients. However, key players in the cancer immunotherapy market are leveraging this opportunity to reach the optimum efficacy level of therapeutics to treat cancer with minimal side effects.

Key requisite to achieve product innovation is high working capital for experimentation and clinical trials, which poses challenges for manufacturers. Besides this, the risk of drug rejection leads to the wastage of resources. Studies also estimate that only 5% of anticancer drugs gain commercial license, post the success of Phase III trials, which is indicative of the high rejection rate of therapeutics in the cancer immunotherapy industry.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Start-up Ecosystem

  • Nouscom is a Swiss start-up that manufactures viral-vectored genetic vaccines. The company offers NOUS-209, its leading immunotherapy candidate effective in the treatment of microsatellite instability (MSI) tumors and mismatch repair deficiency (dMMR).
  • Palleon Pharmaceuticals is a start-up based in the United States that is focused on the development of immunosuppressive sialoglycan-sensing receptors in cells to treat cancer tumors. The company offers two technology platforms EAGLE (Enzyme-Antibody Glyco-Ligand Editing) and Convergence.

Country-wise Analysis

Why Do Cancer Immunotherapy Producers Have Huge Research and Manufacturing Units in the United States?

“Supportive Government Policies Boosting Growth of Cancer Drug Suppliers”

Attribute United States
Market Value (2024E) US$ 16.9 Billion
Growth Rate (2024 to 2034) 10.5% CAGR
Projected Value (2034F) US$ 45.7 Billion

The United States leads the North American market and is set to capture a share of 45.6% by 2034. This can be attributed to favorable market dynamics such as progressive improvements in healthcare infrastructure and government initiatives in the mode of subsidies supporting key market players in carrying out R&D activities. Furthermore, market players are also expected to receive benefits from the United States federal government, such as tax exemptions and market exclusivity. Growing number of awareness campaigns regarding the diagnosis and treatment of cancer is also complementing cancer immunotherapy demand growth in the United States.

Will Rising Cancer Prevalence Push Immunotherapy Demand in Japan?

“Rapidly Increasing Geriatric Population with Chronic Disorders and Altering Lifestyles of Adults”

Attribute Japan
Market Value (2024E) US$ 10.3 Billion
Growth Rate (2024 to 2034) 10.5% CAGR
Projected Value (2034F) US$ 28 Billion
  • According to a BMC Medicine report, Asia accounts for half of the global cancer burden, with cancer incidence projected to rise to nearly 10.6 million by 2030.
  • Japan is estimated to account for 28.9% of the East Asia market share in 2024.

Rapidly aging population, busy and stressful lifestyles, and socio-economic changes are expected to be lead to increasing cases of cancer in Japan. Most common cancer types include those of the lungs, breast, and colon. Furthermore, increased healthcare spending on developing advanced research & development facilities for designing high-grade oncology diagnostics and treatment solutions is set to boost the cancer immunotherapy market growth by 2034.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Category-wise Analysis

Which Cancer Type is Driving High Demand for Effective Immunotherapy?

“Lung Cancer Most Common Type of Malignancy”

  • According to the American Cancer Society, around one-quarter of deaths are due to lung cancer in the United States. Apart from prostate cancer in men and breast cancer in women, lung cancer is the most common cancer diagnosed in people. This is believed to be due to increased smoking habits and intake of harmful drugs.

In addition, chances of lung cancer being detected at an early stage are less. Thus, rising cases of lung cancer worldwide are driving target patients’ attention toward cancer immunotherapies for better treatment.

What’s Boosting Demand for Immune Checkpoint Inhibitors?

“Ability of Immune Checkpoint Inhibitors to Trigger Antitumor Immune Response”

Attribute Immune Checkpoint Inhibitors
Segment Value (2024E) US$ 38.5 Billion
Growth Rate (2024 to 2034) 10.1% CAGR
Projected Value (2034F) US$ 100.7 Billion

Immune checkpoints are a part of the immune system that majorly focus on the protection of healthy cells in the body during the treatment process. Immune checkpoint inhibitors stop the 'off' signal transmission and allow T cells to kill cancer. Immune checkpoint inhibitors are majorly used for the treatment of cancer.

Monoclonal antibody-based drugs also assist in flagging cancer cells, triggering cell-membrane destruction, inhibiting malignant cell proliferation, preventing blood vessel growth, easy chemotherapy delivery, and binding cancer and immune cells among other benefits.

Why Do Cancer Research Centers Account for a Leading Market Share?

“Cancer Research Centers Offer Advanced and Effective Immunotherapies”

Attribute Cancer Research Centers
Segment Value (2024E) US$ 43.9 Billion
Growth Rate (2024 to 2034) 10% CAGR
Projected Value (2034F) US$ 113.9 Billion

Even though hospitals are the most favored medical settings, cancer research centers are equipped with advanced technologies that help offer effective diagnosis and treatment. Cancer research centers are institutions where studies related to cancer, research, and development of advanced diagnostic and treatment procedures are carried out. These centers also offer treatment to cancer patients.

Presence of advanced diagnostics and treatment equipment, medical professionals, and scientists, as well as therapeutics, supported by public and private funding, further improves the healthcare quality offered by research centers.

Competitive Landscape

Leading companies are capitalizing on conducting extensive clinical trials to verify the efficacy of various immunotherapy approaches, including vaccinations and oral drugs. Furthermore, market players are funding research studies to ascertain patterns of cancer prevalence across key geographies.

  • In March 2024, the United States Food and Drug Administration (FDA) approved Bristol Myers Squibb’s ‘Opdivo® (nivolumab)’ in combination with gemcitabine and cisplatin for the first-line treatment of unresectable or metastatic urothelial carcinoma (UC) of adult patients.
  • In 2021, Amgen Plc. announced its first combination study results from its Phase 1b/2 CodeBreaK 101 study, a comprehensive global clinical development program in patients with KRAS G12C-mutated advanced colorectal cancer. It showed that combining LUMAKRASTM (sotorasib) with Vectibix® (panitumumab) demonstrates efficacy and safety.
  • In September 2021, Bristol-Myers Squibb Company conducted a survey that included 250 oncologists, surgeons, and specialists from countries such as the United States, Germany, and Japan. The survey revealed that immunotherapy has the potential to kill early-stage cancer.

Fact.MR provides detailed information about the price points of key providers of cancer immunotherapies positioned across the world, sales growth, production capacity, and speculative technological expansion, in the recently updated market report.

Key Segments of Cancer Immunotherapy Market Research

  • By Therapy :

    • Monoclonal Antibodies
    • Immune Checkpoint Inhibitors
    • Immune System Modulators
    • Cancer Immunotherapy Vaccines
    • Others
  • By Cancer Type :

    • Lung
    • Colorectal
    • Breast
    • Prostate
    • Melanoma
    • Blood
    • Others
  • By End User :

    • Hospitals
    • Ambulatory Surgical Centers
    • Cancer Research Centers
    • Clinics
  • By Region :

    • North America
    • Latin America
    • Western Europe
    • Eastern Europe
    • East Asia
    • South Asia & Pacific
    • Middle East & Africa

Table of Content

1. Executive Summary

2. Industry Introduction, including Taxonomy and Market Definition

3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments

4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections

5. Pricing Analysis

6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034

    6.1. Therapy

    6.2. Cancer Type

    6.3. End User

7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Therapy

    7.1. Monoclonal Antibodies

    7.2. Immune Checkpoint Inhibitors

    7.3. Immune System Modulators

    7.4. Vaccines

    7.5. Others

8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Cancer Type

    8.1. Lung

    8.2. Colorectal

    8.3. Breast

    8.4. Prostate

    8.5. Melanoma

    8.6. Blood

    8.7. Others

9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by End User

    9.1. Hospitals

    9.2. Ambulatory Surgical Centers

    9.3. Cancer Research Centers

    9.4. Clinics

10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region

    10.1. North America

    10.2. Latin America

    10.3. Western Europe

    10.4. Eastern Europe

    10.5. East Asia

    10.6. South Asia & Pacific

    10.7. Middle East & Africa

11. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries

12. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries

13. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries

14. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries

15. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries

16. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries

17. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries

18. Sales Forecast 2024 to 2034 by Therapy, Cancer Type, End User, and Region for 30 Countries

19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard

20. Company Profile

    20.1. Eli Lilly and Company

    20.2. Pfizer, Inc.

    20.3. Spectrum Pharmaceuticals, Inc.

    20.4. GlaxoSmithKline Plc.

    20.5. Amgen Inc.

    20.6. Bristol-Myers Squibb Company

    20.7. Janssen Biotech, Inc.

    20.8. Novartis AG

    20.9. AstraZeneca Plc.

    20.10. F. Hoffmann-La Roche Ltd.

    20.11. Merck & Co., Inc.

    20.12. Sanofi

    20.13. Takeda Pharmaceuticals

    20.14. Immunocore, Ltd

21. Assumptions and Acronyms Therapyd

22. Research Methodology

Don't Need a Global Report?

save 40%! on Country & Region specific reports

List Of Table

Table 01: Global Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023

Table 02: Global Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034

Table 03: Global Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034

Table 04: Global Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023

Table 05: Global Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034

Table 06: Global Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034

Table 07: Global Market Value (US$ Mn) Analysis, by End User, 2019 to 2023

Table 08: Global Market Value (US$ Mn) Analysis, by End User, 2024 to 2034

Table 09: Global Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034

Table 10: Global Market Value (US$ Mn) Analysis, by Region, 2019 to 2023

Table 11: Global Market Value (US$ Mn) Analysis, by Region, 2024 to 2034

Table 12: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2024 to 2034

Table 13: North America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023

Table 14: North America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034

Table 15: North America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034

Table 16: North America Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023

Table 17: North America Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034

Table 18: North America Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034

Table 19: North America Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023

Table 20: North America Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034

Table 21: North America Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034

Table 22: North America Market Value (US$ Mn) Analysis, by End User, 2019 to 2023

Table 23: North America Market Value (US$ Mn) Analysis, by End User, 2024 to 2034

Table 24: North America Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034

Table 25: Latin America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023

Table 26: Latin America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034

Table 27: Latin America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034

Table 28: Latin America Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023

Table 29: Latin America Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034

Table 30: Latin America Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034

Table 31: Latin America Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023

Table 32: Latin America Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034

Table 33: Latin America Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034

Table 34: Latin America Market Value (US$ Mn) Analysis, by End User, 2019 to 2023

Table 35: Latin America Market Value (US$ Mn) Analysis, by End User, 2024 to 2034

Table 36: Latin America Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034

Table 37: Western Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023

Table 38: Western Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034

Table 39: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034

Table 40: Western Europe Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023

Table 41: Western Europe Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034

Table 42: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034

Table 43: Western Europe Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023

Table 44: Western Europe Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034

Table 45: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034

Table 46: Western Europe Market Value (US$ Mn) Analysis, by End User, 2019 to 2023

Table 47: Western Europe Market Value (US$ Mn) Analysis, by End User, 2024 to 2034

Table 48: Western Europe Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034

Table 49: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023

Table 50: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034

Table 51: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034

Table 52: Eastern Europe Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023

Table 53: Eastern Europe Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034

Table 54: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034

Table 55: Eastern Europe Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023

Table 56: Eastern Europe Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034

Table 57: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034

Table 58: Eastern Europe Market Value (US$ Mn) Analysis, by End User, 2019 to 2023

Table 59: Eastern Europe Market Value (US$ Mn) Analysis, by End User, 2024 to 2034

Table 60: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034

Table 61: East Asia Market Value (US$ Mn) Analysis, by Country, 2019 to 2023

Table 62: East Asia Market Value (US$ Mn) Analysis, by Country, 2024 to 2034

Table 63: East Asia Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034

Table 64: East Asia Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023

Table 65: East Asia Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034

Table 66: East Asia Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034

Table 67: East Asia Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023

Table 68: East Asia Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034

Table 69: East Asia Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034

Table 70: East Asia Market Value (US$ Mn) Analysis, by End User, 2019 to 2023

Table 71: East Asia Market Value (US$ Mn) Analysis, by End User, 2024 to 2034

Table 72: East Asia Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034

Table 73: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2019 to 2023

Table 74: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2024 to 2034

Table 75: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034

Table 76: South Asia & Pacific Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023

Table 77: South Asia & Pacific Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034

Table 78: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034

Table 79: South Asia & Pacific Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023

Table 80: South Asia & Pacific Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034

Table 81: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034

Table 82: South Asia & Pacific Market Value (US$ Mn) Analysis, by End User, 2019 to 2023

Table 83: South Asia & Pacific Market Value (US$ Mn) Analysis, by End User, 2024 to 2034

Table 84: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034

Table 85: MEA Market Value (US$ Mn) Analysis, by Country, 2019 to 2023

Table 86: MEA Market Value (US$ Mn) Analysis, by Country, 2024 to 2034

Table 87: MEA Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034

Table 88: MEA Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023

Table 89: MEA Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034

Table 90: MEA Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034

Table 91: MEA Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023

Table 92: MEA Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034

Table 93: MEA Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034

Table 94: MEA Market Value (US$ Mn) Analysis, by End User, 2019 to 2023

Table 95: MEA Market Value (US$ Mn) Analysis, by End User, 2024 to 2034

Table 96: MEA Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

List Of Figures

Figure 01: Global Market Value (US$ Mn) Historical Analysis, 2019 to 2023

Figure 02: Global Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034

Figure 03: Global Market Value Y-o-Y Growth and Forecast, 2019 to 2034

Figure 04: Global Market Incremental $ Opportunity, 2024 to 2034

Figure 05: Global Market Share and BPS Analysis by Therapy, 2024 & 2034

Figure 06: Global Market Y-o-Y Growth Projections by Therapy, 2024 to 2034

Figure 07: Global Market Attractiveness Analysis by Therapy, 2024 to 2034

Figure 08: Global Market Share and BPS Analysis by Cancer Type, 2024 & 2034

Figure 09: Global Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034

Figure 10: Global Market Attractiveness Analysis by Cancer Type, 2024 to 2034

Figure 11: Global Market Share and BPS Analysis by End User, 2024 & 2034

Figure 12: Global Market Y-o-Y Growth Projections by End User, 2024 to 2034

Figure 13: Global Market Attractiveness Analysis by End User, 2024 to 2034

Figure 14: Global Market Share and BPS Analysis by Region, 2024 & 2034

Figure 15: Global Market Y-o-Y Growth Projections by Region, 2024 to 2034

Figure 16: Global Market Attractiveness Analysis by Region, 2024 to 2034

Figure 17: North America Market Value (US$ Mn) Historical Analysis, 2019 to 2023

Figure 18: North America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034

Figure 19: North America Market Value Y-o-Y Growth and Forecast, 2034

Figure 20: North America Market Incremental $ Opportunity, 2024 to 2034

Figure 21: North America Market Share Analysis by Country, 2024 & 2034

Figure 22: North America Market Y-o-Y Growth Projection by Country, 2024 to 2034

Figure 23: North America Market Attractiveness Analysis by Country, 2024 to 2034

Figure 24: North America Market Share and BPS Analysis by Therapy, 2024 & 2034

Figure 25: North America Market Y-o-Y Growth Projections by Therapy, 2024 to 2034

Figure 26: North America Market Attractiveness Analysis by Therapy, 2024 to 2034

Figure 27: North America Market Share and BPS Analysis by Cancer Type, 2024 & 2034

Figure 28: North America Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034

Figure 29: North America Market Attractiveness Analysis by Cancer Type, 2024 to 2034

Figure 30: North America Market Share and BPS Analysis by End User, 2024 & 2034

Figure 31: North America Market Y-o-Y Growth Projections by End User, 2024 to 2034

Figure 32: North America Market Attractiveness Analysis by End User, 2024 to 2034

Figure 33: Latin America Market Value (US$ Mn) Historical Analysis, 2019 to 2023

Figure 34: Latin America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034

Figure 35: Latin America Market Value Y-o-Y Growth and Forecast, 2019 to 2034

Figure 36: Latin America Market Incremental $ Opportunity, 2024 to 2034

Figure 37: Latin America Market Share Analysis by Country, 2024 & 2034

Figure 38: Latin America Market Y-o-Y Growth Projection by Country, 2024 to 2034

Figure 39: Latin America Market Attractiveness Analysis by Country, 2024 to 2034

Figure 40: Latin America Market Share and BPS Analysis by Therapy, 2024 & 2034

Figure 41: Latin America Market Y-o-Y Growth Projections by Therapy, 2024 to 2034

Figure 42: Latin America Market Attractiveness Analysis by Therapy, 2024 to 2034

Figure 43: Latin America Market Share and BPS Analysis by Cancer Type, 2024 & 2034

Figure 44: Latin America Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034

Figure 45: Latin America Market Attractiveness Analysis by Cancer Type, 2024 to 2034

Figure 46: Latin America Market Share and BPS Analysis by End User, 2024 & 2034

Figure 47: Latin America Market Y-o-Y Growth Projections by End User, 2024 to 2034

Figure 48: Latin America Market Attractiveness Analysis by End User, 2024 to 2034

Figure 49: Western Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023

Figure 50: Western Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034

Figure 51: Western Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034

Figure 52: Western Europe Market Incremental $ Opportunity, 2024 to 2034

Figure 53: Western Europe Market Share Analysis by Country, 2024 & 2034

Figure 54: Western Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034

Figure 55: Western Europe Market Attractiveness Analysis by Country, 2024 to 2034

Figure 56: Western Europe Market Share and BPS Analysis by Therapy, 2024 & 2034

Figure 57: Western Europe Market Y-o-Y Growth Projections by Therapy, 2024 to 2034

Figure 58: Western Europe Market Attractiveness Analysis by Therapy, 2024 to 2034

Figure 59: Western Europe Market Share and BPS Analysis by Cancer Type, 2024 & 2034

Figure 60: Western Europe Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034

Figure 61: Western Europe Market Attractiveness Analysis by Cancer Type, 2024 to 2034

Figure 62: Western Europe Market Share and BPS Analysis by End User, 2024 & 2034

Figure 63: Western Europe Market Y-o-Y Growth Projections by End User, 2024 to 2034

Figure 64: Western Europe Market Attractiveness Analysis by End User, 2024 to 2034

Figure 66: Eastern Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023

Figure 67: Eastern Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034

Figure 68: Eastern Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034

Figure 69: Eastern Europe Market Incremental $ Opportunity, 2024 to 2034

Figure 70: Eastern Europe Market Share Analysis by Country, 2024 & 2034

Figure 71: Eastern Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034

Figure 72: Eastern Europe Market Attractiveness Analysis by Country, 2024 to 2034

Figure 73: Eastern Europe Market Share and BPS Analysis by Therapy, 2024 & 2034

Figure 74: Eastern Europe Market Y-o-Y Growth Projections by Therapy, 2024 to 2034

Figure 75: Eastern Europe Market Attractiveness Analysis by Therapy, 2024 to 2034

Figure 76: Eastern Europe Market Share and BPS Analysis by Cancer Type, 2024 & 2034

Figure 77: Eastern Europe Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034

Figure 78: Eastern Europe Market Attractiveness Analysis by Cancer Type, 2024 to 2034

Figure 79: Eastern Europe Market Share and BPS Analysis by End User, 2024 & 2034

Figure 80: Eastern Europe Market Y-o-Y Growth Projections by End User, 2024 to 2034

Figure 81: Eastern Europe Market Attractiveness Analysis by End User, 2024 to 2034

Figure 82: East Asia Market Value (US$ Mn) Historical Analysis, 2019 to 2023

Figure 83: East Asia Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034

Figure 84: East Asia Market Value Y-o-Y Growth and Forecast, 2019 to 2034

Figure 85: East Asia Market Incremental $ Opportunity, 2024 to 2034

Figure 86: East Asia Market Share Analysis by Country, 2024 & 2034

Figure 87: East Asia Market Y-o-Y Growth Projection by Country, 2024 to 2034

Figure 88: East Asia Market Attractiveness Analysis by Country, 2024 to 2034

Figure 89: East Asia Market Share and BPS Analysis by Therapy, 2024 & 2034

Figure 90: East Asia Market Y-o-Y Growth Projections by Therapy, 2024 to 2034

Figure 91: East Asia Market Attractiveness Analysis by Therapy, 2024 to 2034

Figure 92: East Asia Market Share and BPS Analysis by Cancer Type, 2024 & 2034

Figure 93: East Asia Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034

Figure 94: East Asia Market Attractiveness Analysis by Cancer Type, 2024 to 2034

Figure 95: East Asia Market Share and BPS Analysis by End User, 2024 & 2034

Figure 96: East Asia Market Y-o-Y Growth Projections by End User, 2024 to 2034

Figure 97: East Asia Market Attractiveness Analysis by End User, 2024 to 2034

Figure 98: South Asia & Pacific Market Value (US$ Mn) Historical Analysis, 2019 to 2023

Figure 99: South Asia & Pacific Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034

Figure 100: South Asia & Pacific Market Value Y-o-Y Growth and Forecast, 2019 to 2034

Figure 101: South Asia & Pacific Market Incremental $ Opportunity, 2024 to 2034

Figure 102: South Asia & Pacific Market Share Analysis by Country, 2024 & 2034

Figure 103: South Asia & Pacific Market Y-o-Y Growth Projection by Country, 2024 to 2034

Figure 104: South Asia & Pacific Market Attractiveness Analysis by Country, 2024 to 2034

Figure 105: South Asia & Pacific Market Share and BPS Analysis by Therapy, 2024 & 2034

Figure 106: South Asia & Pacific Market Y-o-Y Growth Projections by Therapy, 2024 to 2034

Figure 107: South Asia & Pacific Market Attractiveness Analysis by Therapy, 2024 to 2034

Figure 108: South Asia & Pacific Market Share and BPS Analysis by Cancer Type, 2024 & 2034

Figure 109: South Asia & Pacific Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034

Figure 110: South Asia & Pacific Market Attractiveness Analysis by Cancer Type, 2024 to 2034

Figure 111: South Asia & Pacific Market Share and BPS Analysis by End User, 2024 & 2034

Figure 112: South Asia & Pacific Market Y-o-Y Growth Projections by End User, 2024 to 2034

Figure 113: South Asia & Pacific Market Attractiveness Analysis by End User, 2024 to 2034

Figure 114: MEA Market Value (US$ Mn) Historical Analysis, 2019 to 2023

Figure 115: MEA Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034

Figure 116: MEA Market Value Y-o-Y Growth and Forecast, 2019 to 2034

Figure 117: MEA Market Incremental $ Opportunity, 2024 to 2034

Figure 118: MEA Market Share Analysis by Country, 2024 & 2034

Figure 119: MEA Market Y-o-Y Growth Projection by Country, 2024 to 2034

Figure 120: MEA Market Attractiveness Analysis by Country, 2024 to 2034

Figure 121: MEA Market Share and BPS Analysis by Therapy, 2024 & 2034

Figure 122: MEA Market Y-o-Y Growth Projections by Therapy, 2024 to 2034

Figure 123: MEA Market Attractiveness Analysis by Therapy, 2024 to 2034

Figure 124: MEA Market Share and BPS Analysis by Cancer Type, 2024 & 2034

Figure 125: MEA Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034

Figure 126: MEA Market Attractiveness Analysis by Cancer Type, 2024 to 2034

Figure 127: MEA Market Share and BPS Analysis by End User, 2024 & 2034

Figure 128: MEA Market Y-o-Y Growth Projections by End User, 2024 to 2034

Figure 129: MEA Market Attractiveness Analysis by End User, 2024 to 2034

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

- FAQs -

How big is the cancer immunotherapy market in 2024?

The global cancer immunotherapy market is evaluated at US$ 159.2 billion in 2024.

What is the projected size of the cancer immunotherapy industry by 2034?

The market for cancer immunotherapies is projected to reach US$ 412.8 billion by 2034.

At what rate is the demand for cancer immunotherapies forecasted to rose?

Demand for cancer immunotherapies is foreseen to increase at a CAGR of 10% from 2024 to 2034.

How much is the North American market likely to be valued by 2034?

The North American market is forecasted to reach US$ 100.3 billion by 2034.

How fast is the demand for cancer immunotherapies increasing in Japan?

Cancer immunotherapy demand is calculated to increase at a CAGR of 10.5% in Japan during the next 10 years.

Which type of therapy is widely adopted?

Immune checkpoint inhibitor sales are set to reach US$ 100.7 billion by 2034.

Who are the leading providers of cancer immunotherapies?

Some of the key companies are Pfizer, Inc., Spectrum Pharmaceuticals, Inc., GlaxoSmithKline Plc., Amgen Inc., and Bristol-Myers Squibb Company.

What is the market trend in immunotherapy?

One of the market trends is the development of personalized and combination therapies to offer effective and tailored treatment approaches.

- Also of Interest -

Peptide-based Cancer Therapeutics Market

Peptide-based Cancer Therapeutics Market Analysis Goserelin, Bortezomib, and leuprorelin Drug Types from 2023 to 2033

Cancer Biomarkers Market

Cancer Biomarkers Market Analysis by Test Type (PSA Tests CTC Tests, AFP Tests, CA Tests, HER2 Tests, BRCA Tests, ALK Tests, KRAS Mutation Tests), by Illness Indication (Blood Cancer, Prostate Cancer, Ovarian Cancer, Stomach Cancer, Liver Cancer), by Region - Global Insights 2022-2032

Cancer Profiling Market

Cancer Profiling Market By Product (Instruments, Consumables), By Indication (Breast, Colorectal, Ovarian, Melanoma, Kidney, Lung and Rare Cancer), By End User, By Test Cancer, By Region - Global Market Insights 2021 to 2031

Anti-cancer Drugs Market

Anti-cancer Drugs Market Analysis by Cytotoxics, Hormonal Therapy, and Targeted Therapy for Prostate Cancer, Lung Cancer, Breast Cancer, Melanoma, and Colon & Rectum Cancer from 2024 to 2034

Cancer Immunotherapy Market

Schedule a Call